The short answer
Bromelain could plausibly add to bleeding risk during warfarin treatment, but the inspected evidence does not establish a clinical bleeding increase for the exact combination. The concern comes from older labeling and laboratory work. It is a reason for a clinician to assess co-use, not a quantified or proven interaction rate.
What this answer covers
Oral bromelain supplements with oral warfarin. Bromelain is a protease mixture; pineapple foods, injectable experimental doses and topical burn treatments are different exposures.
- Supplement or preparation
- Bromelain
- Medication ingredient
- warfarin
What does the evidence show?
An older warfarin label lists bromelains among products reported to increase anticoagulant effects. The currently inspected label instead gives broader botanical monitoring advice. A primary experiment found that bromelain reduced aggregation of isolated human platelets and altered thrombus formation in rats. Warfarin-treated patients were not studied in that experiment. A laboratory platelet result explains why an interaction is plausible, but does not show that a swallowed supplement produces the same exposure or causes bleeding in people taking warfarin.
Which forms and conditions matter?
Enzyme activity, preparation and route matter. A milligram of one bromelain product does not necessarily represent the same proteolytic activity as another. Rat oral and intravenous doses cannot be used to calculate a safe human supplement dose. The evidence also does not justify treating pineapple eaten as food as equivalent to concentrated bromelain capsules.
What should I discuss with my care team?
Have the anticoagulation clinician or pharmacist assess the exact bromelain product before use. The clinician may consider closer INR and symptom monitoring when a botanical supplement changes. The retrieved sources provide no validated dose-separation interval and no basis for changing warfarin on your own. Any unusual bleeding warrants prompt medical assessment.
How certain is the answer?
Targeted searches of the biomedical literature and regulatory material did not identify an inspected direct human warfarin-bromelain trial. That finding leaves uncertainty; it does not prove absence of an interaction. Older warnings and mechanistic evidence should not be labeled high-quality clinical proof, nor should the lack of a trial be presented as reassurance that co-use is safe.
Evidence and practical considerations
Side effects & toxicity
Bromelain could plausibly add to bleeding risk during warfarin treatment, but the inspected evidence does not establish a clinical bleeding increase for the exact combination. The concern comes from older labeling and laboratory work. It is a reason for a clinician to assess co-use, not a quantified or proven interaction rate.
- Exact scope
- Oral bromelain supplements with oral warfarin. Bromelain is a protease mixture; pineapple foods, injectable experimental doses and topical burn treatments are different exposures. with Oral warfarin, including warfarin sodium tablets with the warfarin active moiety.
- Medication form and route
- oral warfarin
- Timing or duration
- Study-specific durations are described in each source exposure; no universally safe exposure duration has been established.
What remains uncertain
- Targeted searches of the biomedical literature and regulatory material did not identify an inspected direct human warfarin-bromelain trial. That finding leaves uncertainty; it does not prove absence of an interaction. Older warnings and mechanistic evidence should not be labeled high-quality clinical proof, nor should the lack of a trial be presented as reassurance that co-use is safe.
Factors that may matter: Exact supplement preparation and other ingredients; Starting, stopping or changing supplement intake; Baseline anticoagulation control and clinician-supervised monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral warfarin sodium tablets.
The label advises closer INR monitoring when botanicals are started or stopped, identifies variable botanical composition and lists selected potential interactions. Vitamin K intake should remain consistent.
How this applies: Oral warfarin sodium has warfarin as its active moiety. Label-level botanical and vitamin K monitoring advice applies; it is not proof of this exact supplement effect. Oral bromelain supplements with oral warfarin. Bromelain is a protease mixture; pineapple foods, injectable experimental doses and topical burn treatments are different exposures.
Regulatory precautions do not quantify the incidence for every exact preparation or prove an interaction for an unlisted ingredient. Warfarin sodium is bridged to the warfarin active moiety only for the oral product.
Source 2: archived U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving oral warfarin.
Bromelains appear among supplements associated with possible potentiation of warfarin effects.
How this applies: General warfarin monitoring guidance applies to this pair; the exact-pair conclusion relies on the source-specific evidence and limitations below. Exact package scope: Oral bromelain supplements with oral warfarin. Bromelain is a protease mixture; pineapple foods, injectable experimental doses and topical burn treatments are different exposures.
Historical label precaution, not a controlled bromelain-warfarin trial or the current Teva label. It does not supply an exact formulation, event rate or prevention interval.
Source 3: laboratory and animal study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Isolated human platelets, bovine endothelial cells and rats, not patients taking warfarin.
Bromelain inhibited platelet aggregation and adhesion in laboratory assays and reduced thrombosis measures in rats.
How this applies: Bromelain platelet and animal experiments without warfarin. Biological plausibility only, not a demonstrated exact-pair clinical outcome. Exact package scope: Oral bromelain supplements with oral warfarin. Bromelain is a protease mixture; pineapple foods, injectable experimental doses and topical burn treatments are different exposures.
No human warfarin combination, no clinical bleeding outcome, no oral supplement dose-equivalence demonstrated. Mechanistic plausibility only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and contradictory findings assessed for this exact pair. Article drafted and existing statements adjudicated. Clinical sign-off has not been recorded. | |
| Research summary published |
Article revision: b827c4f3c34e44bd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.